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Wen-Rong Lie,2 Rebecca L. Aft,3 Lynn A. Cornelius,4 Kathryn M. Trinkaus,5 and Gerald P. Linette1
1Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.  
2EMD Millipore, St. Charles, Missouri, USA. 3Department of Surgery, 4Department of Medicine, Division of Dermatology,  
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Background. Systemic administration of IL-12p70 has demonstrated clinical activity in cancer patients, but dose-
limiting toxicities have hindered its incorporation in vaccine formulations. Here, we report on the immunological 
and clinical outcomes upon vaccination with CD40L/IFN-γ–matured, IL-12p70–producing DCs.
Methods. 7 HLA-A*0201+ newly diagnosed stage IV melanoma patients were immunized against the gp100 melano-
ma antigen using autologous peptide-pulsed, CD40L/IFN-γ–matured DCs. PBMCs were taken weekly for immune 
monitoring by tetramer analysis and functional assays. CT imaging was performed at baseline, week 9, and week 18 
for clinical assessment using RECIST.
Results. 6 of 7 treated patients developed sustained T cell immunity to all 3 melanoma gp100 antigen–derived pep-
tides. 3 of the 6 immunological responders developed confirmed clinical responses (1 complete remission >4 years, 
2 partial response). Importantly, DC vaccine–derived IL-12p70 levels positively correlated with time to progression 
(P = 0.019, log-rank), as did T-cytotoxic 1 (Tc1) immunity, as assessed by IFN-γ/IL-13 and IFN-γ/IL-5 ratios (P = 0.035 
and P = 0.030, respectively, log-rank). In contrast, a pathway-specific defect in IL-12p35 transcription was identified 
upon CD40L/IFN-γ activation in clinical nonresponder patient DCs, and gp100-specific T cells from these patients 
displayed a Tc2 phenotype. Incorporation of TLR3 and TLR8 agonists into the CD40L/IFN-γ activation protocol 
corrected the IL-12p70 production defect in DCs derived from clinical nonresponder patients.
Conclusion. These findings underscore the essential role of IL-12p70 in the development of therapeutic type 1 anti-
gen–specific CD8+ T cell immunity in humans with cancer.
Trial registration. Clinicaltrials.gov NCT00683670.
Funding. Barnes-Jewish Hospital Foundation, Siteman Cancer Frontier Fund, Washington University/JNJ Transla-
tional Medicine Award, and NCI (P30 CA91842).
Introduction
DCs are widely regarded as the most potent antigen-presenting 
cells to initiate T cell immunity. Although immature DCs (iDCs) 
can process and present antigens, these cells fail to produce pro-
inflammatory cytokines, and thus have been shown to be tolero-
genic in steady state, or at best weakly immunogenic (1). Stimu-
lation of iDCs with bacterial products, T cell–derived signals, 
and/or inflammatory agonists triggers a differentiation process 
(“maturation”), accompanied by the expression of costimulatory 
molecules and cytokines, which shapes the nature and magnitude 
of T cell–mediated immunity (2). Due to this critical role in the 
innate-to-adaptive immune transition, vaccines using DCs have 
been evaluated in the treatment of patients with metastatic mela-
noma; however, these clinical studies have been disappointing, 
with objective response rates less than 10% (3). Multiple factors 
contribute to the limited success of DC vaccination in melanoma, 
including the tumor microenvironment, Treg-mediated suppres-
sion, immune senescence, as well as incomplete maturation of the 
DCs used for immunization (4, 5). To date, the majority of DC 
vaccine studies have used either iDCs (GM-CSF/IL-4) or partially 
matured DCs (GM-CSF/IL-4 plus activation by IL-1β, IL-6, TNF-α, 
and/or PGE-2), which express costimulatory molecules but fail to 
produce IL-12p70 (6). Production of bioactive IL-12p70 requires 
the coordinated transcriptional regulation of genes encoding the 
IL-12p35 and IL-12p40 subunits (7). Transcriptional activation of 
IL-12p70 is dependent on 2 signals: one initiated by CD40 or TLR 
and the other initiated by IFN-γ (8–10). While both signals are nec-
essary for IL-12p35 transcriptional activation, IL-12p40 activation 
is less dependent on IFN-γ signals. Studies using artificial antigen-
presenting cells provided the initial evidence for the critical role 
of IL-12p70, in conjunction with antigen and B7 costimulation, 
for naive CD8+ T cell expansion and acquisition of effector func-
tion (11). Subsequent work in preclinical models confirmed the 
role of IL-12p70 as a third signal for T cell activation and later 
demonstrated that either IL-12p70 or type I IFN was necessary 
for the development of type 1 CD8+ T cells (12, 13). Among CD8+ 
T cells responding to antigen and costimulation, IL-12p70 signal-
ing enforces a gene regulation program that promotes chromatin 
remodeling and induction of transcription factors, such as T-bet 
and Eomes, that are important in the differentiation program of 
this polarized T cell population, defined as the T-cytotoxic 1 (Tc1) 
phenotype (14). Systemic administration of IL-12p70 has been 
demonstrated to have antitumor activity in various preclinical ani-
mal models as well as modest activity in cancer patients when given 
alone or with cancer vaccines (15–17). However, dose-limiting 
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toxicities associated with systemic IL-12p70 administration have 
hindered a wider incorporation into investigational cancer vaccine 
formulations (18, 19).
Despite experimental evidence supporting the use of IL-12p70 
as a vaccine adjuvant, current human DC vaccine formulations 
fail to incorporate coordinated CD40/TLR/IFNR signaling as 
part of the maturation process; thus, it remains to be determined 
whether vaccination with functionally mature, IL-12p70–produc-
ing DCs confers a benefit to humans with cancer. Our aim was to 
test the hypothesis that immunization with functionally mature, 
IL-12p70–producing DCs would correlate with antigen-specific 
immunity and clinical outcomes in patients with metastatic 
melanoma. In this proof-of-concept clinical trial, patients with 
newly diagnosed metastatic melanoma were immunized against 
3 HLA-A*0201–restricted gp100 melanoma antigen–derived pep-
tides (G154, G209-2M, and G280-9V) (20, 21) using autologous 
peptide-pulsed, CD40L/IFN-γ–activated mature DCs (mDCs). In 
this report, we characterized the induction of T cell immunity by 
weekly longitudinal monitoring using PBMCs and investigated 
biomarkers associated with clinical outcome.
Results
Patient-derived mDCs display varied IL-12p70 production upon CD40L/
IFN-γ activation. To assess the immunological and clinical out-
comes upon vaccination with CD40L/IFN-γ–activated, IL-12p70–
producing mDCs, 7 newly diagnosed treatment-naive stage IV 
melanoma patients were enrolled and treated in a pilot phase I 
clinical trial (Table 1 and Figure 1A). Patients were not prescreened 
for IL-12p70 production prior to enrollment. The schedule of 
cyclophosphamide treatment, DC vaccinations, and immune-
monitoring timelines is depicted in Figure 1B. Cyclophosphamide 
treatment with a single dose (300 mg/m2 i.v.) given 3 days prior 
to DC vaccination dose 1 (D1) did not significantly reduce Treg 
frequencies (Supplemental Figure 2; supplemental material avail-
able online with this article; doi:10.1172/JCI68395DS1) or abso-
lute lymphocyte counts (data not shown) in any of the 7 patients 
treated. For D1, fresh PBMCs were initiated into culture for DC 
generation; the remaining PBMCs were cryopreserved and used 
to generate subsequent DC vaccine doses. 24 hours after CD40L/
IFN-γ activation, each mDC preparation was assessed for expres-
sion of various costimulatory molecules (CD80, CD83, and CD86; 
data not shown) and cytokine production. Consistent with a previ-
ous report (22), DCs derived from cryopreserved PBMCs showed 
reduced IL-12p70 production (Figure 1C). However, DCs gener-
ated from both fresh and frozen PBMCs, as prepared in our trial, 
retained functional capacity, as shown by their equivalent in vitro 
stimulatory capacities (data not shown). More importantly, the 
initial D1 (fresh DCs/fresh PBMCs) and subsequent booster doses 
(fresh DCs/frozen PBMCs) of DC vaccines resulted in increased 
frequencies of gp100 peptide–specific CD8+ T cells (Figure 2), 
demonstrating this scheme to represent a good logistic approach 
to DC vaccine manufacturing.
Unexpectedly, concentrations of IL-12p70 produced by mDCs 
varied dramatically among patients (Figure 1C). For example, 
patient 1 (P1) DCs produced a median of 37,700 pg/106 cells/24 h, 
whereas DCs of P3 produced approximately 370-fold less (<100 pg/ 
106 cells/24 h). Note that the levels shown in Figure 1C (represent-
ing D1–D3) were consistent in all vaccine preparations. Dimin-
ished IL-12p70 production (<1,000 pg/106 cells/24 h) by patient 
DCs upon CD40L/IFN-γ activation was not due to the inability of 
these cells to respond to stimuli, as significant induction of IL-6, 
IL-8, and TNF-α production was observed among normal/high 
(>1 ng/106 cells/24 h) and low (<1 ng/106 cells/24 h) IL-12p70 
producers (Supplemental Figure 3, A and B). Moreover, among 
a panel of 42 cytokines and chemokines analyzed, no deficiency 
other than IL-12p70 was observed in the patients studied (data 
not shown).
CD40L/IFN-γ–activated mDC vaccination elicits gp100-specific T cell 
immunity. To examine the kinetics and magnitude of T cell immu-
nity to the gp100-derived peptides G154, G209-2M, and G280-9V 
upon mDC vaccination, peripheral blood was collected prior to 
vaccination and weekly thereafter (Figure 1B). Isolated PBMCs 
were used to establish individual cultures for each of G154, G209-
2M, and G280-9V. The CD8+ T cell response to each peptide 
antigen was analyzed using peptide/HLA*A0201 tetramers after 
a single round of in vitro stimulation for 12 days. This immune 
monitoring strategy allows for the reliable detection of vaccine-
induced T cell responses in patients, as vaccine-induced T cell 
frequencies are often below the lower limit of detection using cur-
rent ex vivo assays with fresh PBMCs (23). Furthermore, it allows 
for assessment of the replicative potential of vaccine-induced 
T cells based on the multiple cell divisions required for cell expan-
sion in vitro and detection by tetramer assay. Immune monitoring 
after D4 was not shown, since the peak of the CD8+ T cell response 
occurred within the first 9 weeks for all patients (Supplemental 
Figure 4A). P5 and P7 had detectable immunity to all 3 gp100 
peptides prior to vaccination, and these responses increased sig-
nificantly after immunization (Figure 2). Surprisingly, the peak 
T cell response was detected after 1 or 2 mDC vaccine doses in 
most patients (Supplemental Figure 4A). However, the 2 patients 
Table 1
Patient characteristics and immunological and clinical outcomes
Patient Sex AgeA StageB Site of metastasis Clinical status TTPC Immune responeD IL-12p70E
P1 M 47 4 (M1a) Subcutaneous (multiple), lymph node Complete remission 9/23/08; >1,416 d 325 104,794
P2 M 70 4 (M1b) Lung (multiple) Progressive disease 1/16/09; 131 d 311 902
P3 M 53 4 (M1a) Lymph node Progressive disease 5/29/09; 81 d 4.4 63
P4 F 50 4 (M1a) Subcutaneous (solitary) Progressive disease 1/15/10; 74 d 62 287
P5 M 53 4 (M1b) Lung (multiple) Partial response 4/9/10; 352 d 240 2,101
P6 M 38 4 (M1c) Liver (multiple) Partial response 4/13/10; 444 d 301 2,065
P7 M 36 4 (M1b) Lung (multiple), subcutaneous (multiple) Progressive disease 3/15/11; 63 d 295 793
AAt initiation of treatment (yr). BAccording to The American Joint Committee on Cancer staging system (2009 ed.). CDate of analysis, 08/05/12. Dgp100-spe-
cific T cell frequencies for weeks 0–9 (sum); see Figure 2. EProduction levels for D1–D3 (sum; pg/106 DCs/24 h); see Figures 1 and 4.
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with the lowest gp100-specific T cell responses and the lowest DC 
IL-12p70 production levels (P3 and P4) had delayed kinetics, with 
the peak response detected after 3 vaccine doses (Figure 1C, Figure 
2, and Supplemental Figure 4A). Analysis of CD8+ T cell responses 
to individual gp100-derived peptides indicated that all patients 
developed immunity to the G209-2M peptide (4.6%–48% CD8+ 
T cells), while all patients but P3 developed immunity to the G154 
(<10% CD8+ T cells) and G280-9V (11%–70% CD8+ T cells) peptides 
(Figure 2). Interestingly, CD8+ T cell frequencies in response to the 
high-affinity G154 peptide were consistently lower than to those 
observed for the low-affinity G209-2M and G280-9V peptides 
(Supplemental Figure 4B). Overall, mDC vaccination resulted in a 
significant increase in the gp100-specific T cell frequencies for all 
3 peptides (Supplemental Figure 4B). Importantly, immunization 
with CD40L/IFN-γ–activated mDCs pulsed with G209-2M and 
G280-9V elicited antigen-specific CD8+ T cells that recognized the 
naturally processed gp100 antigen and exhibited antigen avidity 
(i.e., effective concentration at 50% maximal lysis) ranging 0.1–1 
nM, as determined in standard 4-hour 51Cr release assays (Figure 
3, A and B). These results suggest that 2 mDC doses are sufficient 
for the induction of high-avidity T cells to native gp100 protein in 
most patients. In the 3 patients that exhibited a confirmed clini-
cal response (P1, P5, and P6; Table 1 and Supplemental Figure 
5), gp100-specific memory T cell responses were detected 6–12 
months after the last vaccination (Supplemental Figure 6), despite 
the fact that ipilimumab followed by temozolomide and steroids 
Figure 1
Clinical trial scheme and ex vivo IL-
12p70 production by CD40L/IFN-γ–
activated DCs (mDCs). (A) Consort 
diagram. (B) Study timelines depicting 
cyclophosphamide treatment (300 mg/
m2 i.v.), DC vaccinations (D1–D6), and 
PBMC sampling for immune monitoring. 
(C) Ex vivo IL-12p70 levels produced by 
patient-derived mDCs used for manufac-
turing D1–D3 (each symbol represent a 
vaccine dose). DC supernatants were 
harvested 24 hours after activation, and 
IL-12p70 concentrations were deter-
mined by ELISA. D1 was manufactured 
using fresh PBMCs (which consistently 
produced the highest concentration of 
cytokine) as the source of monocytes, 
and D2–D6 were prepared using cryo-
preserved PBMCs. Results represent 
mean ± SEM.
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(P6), ipilimumab (P5), or no additional treatment (P1) had been 
administered (see trial summary in the supplemental material).
IL-12p70 production by patient mDCs correlates with clinical outcome. 
Of the 7 patients treated in this pilot trial, 3 had an objective 
clinical response (P1, P5, and P6; Table 1) as assessed by Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria (24), and 
each responding patient had time to progression (TTP) of >11.5 
months. Cox regression analysis followed by likelihood-ratio test 
revealed a positive correlation between ex vivo IL-12p70 produc-
tion by CD40L/IFN-γ–activated mDCs and TTP (P = 0.0198; Figure 
4). P1, the patient vaccinated with mDCs producing the highest 
amounts of IL-12p70 (Table 1), remained in complete remission 
>4 years after enrollment in the clinical trial (Supplemental Figure 
5). In contrast, patients vaccinated with mDCs producing relatively 
low amounts of IL-12p70 (<1 ng IL-12p70, sum D1–D3; Table 1) 
had rapid disease progression, confirmed upon CT imaging per-
formed after D3 or D6 (data not shown). Only those patients vacci-
nated with mDCs producing >1 ng IL-12p70 (Table 1) had clinical 
benefit, as defined by increased TTP as well as tumor regression 
(Supplemental Figure 5). In contrast, a similar analysis found 
no significant correlation between IL-12p70 production and fre-
quency of vaccine-induced T cell responses or between frequency of 
vaccine-induced T cell responses and TTP in this study.
Vaccine-induced CD8+ T cell responses are qualitatively different between 
clinical responders and nonresponders. Having determined that the mag-
nitude of the vaccine-induced immune response did not correlate 
with clinical benefit, next we examined whether immunization with 
high/normal (>1 ng/106 cells/24 h) and low (<1 ng/106 cells/24 h) 
IL-12p70–producing DCs influences the cytokine profiles of the 
vaccine-induced T cells. G280-9V–specific CD8+ T cells were gener-
ated as previously described (25) and restimulated in an antigen-
specific manner, and supernatants were collected at 20 hours and 
Figure 2
Vaccine-induced CD8+ T cell responses. PBMCs isolated before DC vaccination (pre-vacc) and at peak (post-vacc; see Supplemental Figure 4 
for kinetics) were cultured in vitro in the presence of peptide (40 μg/ml) and IL-2 (50 U/ml) for 12 days. Cultures were stained by addition of cor-
responding PE-conjugated tetramers (gp100 peptide/HLA-A*0201) followed by a lineage-negative cocktail (FITC-conjugated anti-CD4, -CD14, 
-CD19, and -CD56) and allophycocyanin-conjugated anti-CD8. Viability dye 7AAD was added to gate out dead cells. Numbers within dot plots 
represent percent G154 (A), G209-2M (B), and G280-9V (C) tetramer-positive cells in lymph+/CD8+ gated cells.
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tested by a multiplex (42-cytokine) bead assay. Examination of 
IFN-γ, IL-5, and IL-13 production levels revealed 2 distinct cytokine 
profiles among the 6 patients with immunological responses (P3 
could not be evaluated because the frequency of gp100-specific 
T cells was insufficient for analysis). In 1 group of patients (P1, P5, 
and P6), IFN-γ production was dramatically higher than IL-5 and 
IL-13, suggestive of a Tc1 bias immune response, while in another 
group (P2, P4, and P7), higher IL-5 and IL-13 production amounts 
with less IFN-γ was observed, consistent with a Tc2 bias (Figure 5, 
A and B). When patients were grouped according to clinical ben-
efit (clinical responder vs. nonresponder), significant differences 
between these 2 groups were observed in IFN-γ/IL-13 and IFN-γ/
IL-5 ratios (P = 0.0356 and P = 0.0425, respectively; Figure 5C). The 
high IFN-γ/IL-13 and IFN-γ/IL-5 ratios observed in the patients 
immunized with high–IL-12p70–producing mDCs (P1, P5, and P6) 
correlated with an objective clinical response (Table 1). Conversely, 
vaccination with low–IL-12p70–producing mDCs resulted in a 
Tc2-skewed response (low IFN-γ/IL-13 or IFN-γ/IL-5 ratio), which 
may be ineffective at promoting tumor regression and correlated 
with rapid disease progression. Importantly, Tc1 profiles positively 
correlated with TTP (IFN-γ/IL-13, P = 0.035; IFN-γ/IL-5, P = 0.030; 
Kaplan-Meier log-rank test), such that those patients with IFN-γ 
in excess of IL-13 and IL-5 had the longest TTP. Other cytokines 
associated with lineage commitment, such as IL-9, IL-10, and IL-17, 
could not be detected in the supernatants of antigen-stimulated 
gp100-specific CD8+ T cells from patients in this study (data not 
shown). This observation provides evidence that vaccination with 
IL-12p70–producing (>1 ng/106 cells/24 h) mDCs promotes type 
1 immunity that can result in clinical benefit in newly diagnosed 
patients, as defined by objective tumor regression and improved 
progression-free survival.
Decreased IL-12p70 production results from impaired IL-12p35 gene 
activation upon CD40L/IFN-γ stimulation. Having established a sta-
tistically significant correlation between IL-12p70 production 
and clinical outcome (as measured by TTP; Figure 4), we formally 
examined whether IL-12p70 production by DCs upon CD40L/
IFN-γ activation is defective among melanoma patients. iDCs 
derived from 10 newly diagnosed treatment-naive stage IV mela-
noma patients and 10 age- and gender-matched healthy controls 
were generated, then stimulated with CD40L/IFN-γ and super-
natants collected 24 hours later. As shown in Figure 6A, and in 
agreement with our previous results (26), mDCs from healthy 
controls produced a median IL-12p70 concentration of 5.5 ng/106 
cells/24 h; the highest IL-12p70 producer among healthy con-
trols was 24 ng/106 cells/24 h. In contrast, mDCs derived from 
melanoma patients produced a median IL-12p70 concentration 
Figure 3
Vaccine-induced T cells recognize native gp100 and display high affinity for antigen. (A) PBMCs collected after D3 were cultured in the presence 
of G209-2M (white bars and symbols) or G280-9V (black bars and symbols) peptide for 12 days as described in Figure 2 and tested in a standard 
4-hour 51Cr release assay for their ability to recognize native gp100 antigen on human melanoma cells lines DM6 (HLA-A2+gp100+) and A375 
(HLA-A2+gp100–). Percent specific lysis at a 30:1 effector/target ratio is shown; spontaneous lysis was <10%. Results are representative of 2 
experiments. (B) Avidity of G209-2M– and G280-9V–specific T cells was determined in a standard 4-hour 51Cr release assay using peptide titra-
tions and T2 (HLA-A*0201+) cells as targets. Percent specific lysis is shown for each peptide concentration; spontaneous lysis was <5%. Results 
are representative of 2 experiments.
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of 0.65 ng/106 cells/24 h. This 8-fold decrease in median IL-12p70 
production levels was statistically significant (P = 0.0420), despite 
1 melanoma patient producing IL-12p70 levels of >30 ng/106 
cells/24 h. Moreover, mDCs from 7 of the 10 melanoma patients 
produced IL-12p70 levels of <1 ng, while all healthy controls pro-
duced >1 ng (Figure 6A).
To better understand the basis for impaired production of bio-
active IL-12 (IL-12p70, IL-12p35, and IL-12p40), we examined 
the synthesis of IL-12p40 and IL-12p35. As IL-12p35 is secreted 
exclusively as a subunit of the IL-12p70 heterodimer (1:1 ratio 
with IL-12p40), bioactive IL-12 production is generally accepted 
to be an indicator of IL-12p35 production (27). As shown in Fig-
ure 6B, IL-12p40 production was markedly induced in mDCs in 
all patients (10.1–177 ng/106 cells/24 h). A 2.5-fold difference 
was observed between the 25th and 75th quartiles (20.5 and 52.7 
ng/106 cells/24 h, respectively), suggesting similar induction of 
IL-12p40 production among patients. In contrast, IL-12p70 pro-
duction varied substantially (45 pg–33 ng/106 cells/24 h) among 
patients, with an 18-fold difference between the 25th and 75th 
quartiles (63 and 1,170 pg/106 cells/24 h, respectively). These data 
suggested that defective IL-12p35 expression might account for 
the decreased IL-12p70 production. We sought to further confirm 
this finding using quantitative real-time RT-PCR (qRT-PCR) using 
mDCs from the clinical trial participants (no cells were available 
for P4). As shown in Figure 6C, the IL-12p35 transcript was mar-
ginally induced (<3-fold) in DCs from the low IL-12p70 producers 
(P2, P3, and P7), whereas a >15-fold increase was observed in DCs 
derived from the high/normal IL-12p70 producers (P1, P5, and 
P6). Together, these findings suggest that defective IL-12p35 gene 
transcription observed upon CD40L/IFN-γ activation accounts 
for the impaired IL-12p70 production by melanoma patient DCs.
Impaired IL-12p70 production by patient mDCs can be rescued by a 
unique combination of innate and adaptive activating signals. Prior stud-
ies in healthy individuals have demonstrated that TLR agonists can 
synergize with CD40L and/or IFN-γ (28–30) to stimulate IL-12p70 
production. In an effort to correct the IL-12p35 deficiency observed 
upon CD40L/IFN-γ activation, DCs derived from clinical trial par-
ticipants were activated with CD40L/IFN-γ in combination with 
various TLR agonists and IL-12p70 production levels examined. In 
preliminary experiments using single TLR agonists, we determined 
that the TLR3 agonist poly I:C and the TLR8 agonist R848 were 
equipotent when added as single agonists to CD40L/IFN-γ (data 
not shown). Moreover, as shown in Figure 7A, poly I:C, R848, and 
CD40L/IFN-γ in combination enhanced patient DC IL-12p70 pro-
duction 5- to 160-fold above that of CD40L/IFN-γ activation alone. 
Importantly, upon combined CD40L/IFN-γ, poly I:C, and R848 
activation, IL-12p70 production by mDCs from P2, P3, P4, and P7 
reached levels similar to those observed in healthy individuals (Fig-
ure 6A and Figure 7A). Thus, the IL-12p70 deficiency observed in 
patient mDCs upon CD40L/IFN-γ activation appears to be path-
way dependent, not reflective of an overall dysfunction in IL-12p35 
transcription. Finally, as an additional test of functional compe-
tence, mDCs activated with CD40L/IFN-γ, poly I:C, and R848 in 
combination were evaluated for their capacity to promote the ex 
vivo expansion of antigen-specific T cells from selected vaccinated 
patients. As shown in Figure 7, B and C, mDCs activated with com-
bined CD40L/IFN-γ, poly I:C, and R848 enhanced IL-12p70 pro-
duction and showed an improved capacity compared with CD40L/
IFN-γ activation alone, stimulating growth of gp100-specific CD8+ 
T cells and increasing T cell frequencies 2- to 4-fold, as assessed by 
gp100/HLA-A*0201 peptide tetramer assay. Together, these results 
demonstrated that the incorporation of poly I:C and R848 into the 
DC maturation protocol improved IL-12p70 production by mela-
noma patient–derived DCs and may promote enhanced antigen-
specific CD8+ T cell responses.
Discussion
A novel clinical-grade CD40L reagent was developed to test the 
hypothesis that immunization with functionally mature IL-
12p70–producing DCs elicits effective CD8+ T immunity in 
patients with newly diagnosed advanced melanoma. Immuno-
logical responses to the gp100 antigen were observed in 6 of the 
7 treated patients, while clinical response (as defined by RECIST 
criteria) was observed in 3 of 7 patients. Importantly, IL-12p70 
levels produced by patient-derived CD40L/IFN-γ–activated mDCs 
as well as the development of antitumor Tc1 CD8+ T cell immu-
nity correlated with TTP. Impairment in IL-12p70 production 
by CD40L/IFN-γ activated mDCs was observed in the 4 clinical 
nonresponder patients (all with Tc2-skewed immunity), and this 
deficiency resulted from impaired IL-12p35 subunit transcription. 
However, incorporating TLR3 and TLR8 signals with CD40L/
IFN-γ activation corrected the IL-12p70 production defect in clini-
cal nonresponder patient DCs, suggesting new ways to improve 
vaccine efficacy in patients with cancer.
Progress in cancer immunotherapy has been hampered by the 
lack of clinical-grade reagents available to investigators (31); thus, 
to the best of our knowledge, this study represents the first DC vac-
cine trial to use the combination of trimeric (cell-bound) CD40L 
with IFN-γ for ex vivo DC maturation prior to administration. 
Previous human studies have used clinical-grade soluble trimeric 
CD40L as a single agent applied to mDCs ex vivo (32, 33), but 
neither reported or attempted to correlate IL-12p70 production 
with immunological responses and/or clinical outcomes. More 
recently, Okada et al. (34) demonstrated, in malignant glioma, 
the immunogenicity and clinical activity of a poly-ICLC–boosted 
α–type 1 polarized DC vaccine and correlated clinical benefit (as 
determined by TTP) with the ability of these type 1 polarized DCs 
to in vitro produce IL-12p70 upon CD40L activation. Our results 
Figure 4
IL-12p70 production and TTP. Cox regression analysis followed by likeli-
hood-ratio test revealed a positive correlation between IL-12p70 produc-
tion and TTP (P = 0.0198, log-rank). White symbols represent patients 
with rapid disease progression. Black symbols represent patients with 
confirmed clinical response (see Table 1). P1 showed complete remis-
sion as of 4 years after initiation of treatment (analysis performed on 
08/05/12; asterisk); P5 and P6 showed a partial response, with disease 
progression observed at or after 11.5 months of treatment initiation. No 
correlation was observed between IL-12p70 production and immune 
response or between immune response and clinical outcome.
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immunological and clinical outcomes reported by Timmerman 
et al. (37) using i.v. infused DCs in non-Hodgkin’s lymphoma, we 
chose to administer CD40L/IFN-γ–activated mDCs by i.v. infusion. 
Labeling studies in patients have shown that i.v. injected DCs traf-
fic to the lung and subsequently redistribute to liver, spleen, and 
bone marrow (38, 39). Interestingly, P6 presented multiple liver 
metastases and achieved partial clinical response after vaccina-
tion, suggesting an effect of IL-12p70–producing DCs at or near 
the hepatic lesions. Additionally, our results demonstrated that i.v. 
administration of DCs induced T cell immunity, which suggests 
that the quality of immune response maybe more dependent on 
the maturation status of DCs than on the route of administration. 
However, recent studies have suggested that other routes of vaccine 
administration might be superior (40, 41); additional investigation 
is warranted in this area to further optimize vaccine efficacy.
DC dysfunctions in cancer patients have been previously 
described; most are predicated on tumor-derived factors that 
suppress DC differentiation, maturation, or function within the 
confirmed and extended these findings by providing additional 
evidence in melanoma that immunization with antigen-loaded, 
IL-12p70–producing DC vaccine resulted in the development of 
Tc1 antigen-specific CD8+ T cell immunity that correlated with 
clinical benefit, as defined by radiographic response (RECIST) and 
improved TTP. Importantly, the 3 highest IL-12p70 producers (P1, 
P5, and P6) in our trial were the only patients that had a radio-
graphic response (1 complete remission, 2 partial response), and 
each was associated with TTP of >11.5 months. In contrast, the 
remaining 4 patients (P2, P3, P4, and P7) all had IL-12p70 produc-
tion of <1 ng/106 cells/24 h and exhibited disease progression with 
no evidence of tumor regression at any site. Thus, IL-12p70 pro-
duction levels appear to be a biomarker of clinical benefit (Figure 
4), which suggests that optimization of DC vaccine formulations 
should consider incorporating measurement of IL-12p70 produc-
tion as a surrogate of vaccine potency and efficacy (34, 35).
Despite several comparative studies in humans (3, 36), the opti-
mal route of DC administration remains to be defined. Based on 
Figure 5
gp100 antigen–specific T cells from clinical responders display a Tc1 phenotype. Purified CD8+ T cells were stimulated twice in vitro, and antigen-
specific frequencies were determined by peptide/HLA-A*0201 tetramers. T cells were adjusted to 106 cell/ml and stimulated with antigen, and 
supernatants were harvested at 20 hours. Cytokine production was determined as described in Methods. (A and B) Patients were grouped as 
clinical responders (A) and nonresponders (B). To compare production of Tc1 (IFN-γ) and Tc2 (IL-5, IL-13) cytokines among patients, a cytokine 
index was derived by dividing pg/ml IFN-γ by pg/ml IL-13 or IL-5. (C) Cytokine ratios differed among clinical responder and nonresponder patients. 
P values (unpaired 2-tailed t test) are indicated. Results are representative of 2 experiments.
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water-in-oil emulsions such as Montanide (51), effectively primed 
an immune response to the gp100 antigen; however, the quality of 
the ensuing T cell response is insufficient to elicit tumor regres-
sion. Moreover, the magnitude or duration of CD8+ T cell immu-
nity after immunization was not markedly influenced by IL-12p70 
concentration — although P3, the patient that produced no detect-
able IL-12p70, developed weak, transient T cell immunity against 
only G209-2M, whereas the remaining 6 patients developed sus-
tained immunity against all 3 gp100-derived peptides. Rather, the 
striking bias toward type 1 immunity among the normal/high IL-
12p70 producers was consistent with past observations in murine 
models that show the direct causal influence of IL-12p70 on Th1 
lineage commitment (52, 53). The positive correlation observed 
between cytokine ratios (IFN-γ/IL-13 and IFN-γ/IL-5) and TTP 
was a finding of key importance, providing further support for 
IL-12p70 as a critical signal in the induction of therapeutic type 1 
antigen-specific CD8+ T cell immunity in patients. Our data may 
also provide an explanation for the limited success of various adju-
vants, as well as past DC vaccine trials in cancer, which have not 
incorporated IL-12p70 (3, 54). Future studies using DC activation 
protocols incorporating sequential activation signals, such as TLR3 
and TLR8 agonists, with CD40L/IFN-γ should lead to enhanced 
IL-12p70 production, which is predicted by various investigators to 
elicit therapeutic antitumor type 1 immunity (2, 55–57).
Sample size estimates for investigator-initiated, first-in-human 
clinical trials has become a topic of contention, driven principally 
by the requirement for statistical power balanced by investiga-
tion of a biologic proof of principle (58). Implicit in the testing 
of novel protein-, gene-, or cell-based therapies at single academic 
medical centers is cost. The results of our study support a model 
of adaptive clinical development that requires initial testing of 
expensive therapeutics in a limited number of patients selected 
on the basis of phenotype (disease) or genotype with a focus on 
discovery, rather than a well-defined regulatory endpoint. Recent 
examples that highlight a similar approach of evaluating novel cell 
therapies in a limited number of patients include trials with chi-
meric antigen receptor T cell gene therapy for leukemia (59) and 
α-galactosylceramide–loaded DC vaccination for myeloma (60).
context of the tumor microenvironment (4, 42). The list of tumor-
derived factors includes IL-10, VEGF, M-CSF, TSLP, and TGF-β1 
as well as prostaglandins and gangliosides (5, 43). The observed 
defect in IL-12p70 synthesis upon CD40L/IFN-γ activation in 7 
of 10 patients was also suggestive of a DC dysfunction, albeit one 
that is likely dependent on activation method (CD40L/IFN-γ) and 
perhaps independent of tumor-derived factors. Our observation 
that incorporation of innate signals (TLR3 and TLR8 agonists) 
to the activation protocol restored the capacity of patient’s DCs 
to produce IL-12p70 at levels similar to those observed in healthy 
individuals suggests the IL-12p35 deficiency to be pathway spe-
cific. Interestingly, defective IL-12p70 production by neonate 
DCs has been proposed to account for impaired Th1 responses in 
human newborns (44). In neonate DCs, similar to our study using 
adult monocyte-derived DCs, selective deficiency in IL-12p70 pro-
duction resulted from impaired IL-12p35 transcription upon acti-
vation. Goldman and coworkers have identified defective nucleo-
some remodeling (at the SP-1 site) of the IL-12p35 promoter and 
lack of IRF-3 phosphorylation as mechanisms that may account 
for impaired IL-12p35 transcription in newborn-derived DCs 
(45, 46). However, IFN-γ treatment of neonate DCs can restore 
IL-12p35 transcription and IL-12p70 synthesis. In contrast, in 
melanoma patient–derived DCs, impaired IL-12p35 transcription 
was corrected by addition of TLR agonists, but not by increasing 
concentrations of IFN-γ (data not shown), which suggests that a 
distinct mechanism may account for the impairment. Indeed, pre-
liminary studies examining STAT-1 phosphorylation and nuclear 
translocation of IFN-responsive factors (IRF-1, IRF-8, and IRF-
3) showed no defect in the IFN signaling pathway among DCs 
derived from the nonresponder patients (data not shown).
Substantial evidence supports the hypothesis that Th2/Tc2 
immune polarization correlates with worse disease outcome in 
patients with cancer (47). Previous work using melanoma anti-
gen-specific T cells from patients confirms an immune bias with 
deviation toward the Th2/Tc2 phenotype (48–50). Interestingly, 
this type 2 immune bias could be partially corrected by antigen 
stimulation in vitro using IL-12p70–producing mDCs (48). Our 
present results revealed that low–IL-12p70–producing mDCs, like 
Figure 6
IL-12p70 production and IL-12p35 transcription by mDCs derived from patients with melanoma. (A) DCs from age- and gender-matched healthy 
donors (H) and melanoma patients (M) were activated with CD40L/IFN-γ for 24 hours, and supernatants were harvested and assayed for IL-
12p70 production by ELISA. Horizontal lines and error bars denote median and interquartile range. P value (Wilcoxon matched-pairs test) is 
indicated. (B) Patient DCs were activated with CD40L/IFN-γ for 24 hours, supernatants were collected, and IL-12p40 and IL-12p70 production 
was measured by ELISA. Results are shown for 10 melanoma patients. Horizontal lines and error bars denote median and interquartile range. (C) 
To examine IL-12p35 gene activation, DCs were activated with CD40L/IFN-γ for 6 hours, cells were harvested and washed, and total RNA was 
prepared. Total RNA was also prepared from iDCs. Using primers specific for IL-12p35 and CD11c (DC lineage marker), qRT-PCR was performed 
and analyzed using the relative standard method. Results were normalized to CD11c, and values are expressed as fold IL-12p35 induction in 
mDCs relative to iDCs. Results are representative of 2 experiments.
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Methods
Human subjects. Eligible adult patients with newly diagnosed treatment-
naive (ECOG performance status 0) stage IV cutaneous melanoma were 
enrolled in this clinical trial. All subjects were HLA-A*0201+, had gp100+ 
biopsy-proven (HMB45+, immunohistochemistry) melanoma metastases, 
had no evidence of autoimmune disorder, and were negative for HIV, HBV, 
and HCV. Leukapheresis was performed to obtain PBMCs from patients 
and healthy donors through the Barnes Jewish Hospital blood bank. For 
In summary, this proof-of-concept clinical study provided evidence 
that IL-12p70 produced by antigen-loaded mDCs dictates T cell lin-
eage commitment toward the Tc1 (versus Tc2) phenotype, which then 
influences disease response (or progression) among patients with 
minimal tumor burden. These results highlight the critical role of IL-
12p70 in developing CD8+ T cell immunity and the potential value of 
this cytokine as a surrogate for vaccine efficacy and also suggest new 
strategies to enhance T cell immunity in patients with cancer.
Figure 7
IL-12p70 production and ex vivo antigen-specific T cell responses stimulated by CD40L/IFN-γ + poly I:C + R848–activated DCs. (A) iDCs were 
stimulated for 24 hours with CD40L/IFN-γ (mDCs), alone or in combination with poly I:C (5 μg/ml; TLR3 agonist) and R848 (5 μg/ml; TLR8 ago-
nist), and supernatants were assayed for IL-12p70. Results are those obtained in 2 experiments. P values (paired 2-tailed t test) are indicated. 
(B and C) DCs derived from P3 and P4 were activated for 24 hours with CD40L/IFN-γ, alone or in combination with poly I:C and R848, and 
supernatants were analyzed for IL-12p70. Additionally, activated DCs were pulsed with G280-9V peptide (40 μg/ml) and used for stimulation of 
purified CD8+ T cells (see Methods). G280-9V–specific T cell frequencies within the CD8+ T cell population was determined at day 12 using YLE/
HLA-A*0201 tetramers and anti-CD8 mAb. Results are representative of 3 experiments.
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To assess the antigen-specific T cell frequency, cells were stained with HLA-
A*0201/peptide tetramers (Beckman Coulter) for 30 minutes at room tem-
perature, followed by addition of FITC-conjugated CD4, CD14, CD19, and 
CD56 and allophycocyanin-conjugated CD8 (Invitrogen) for 15 minutes at 
4°C. Cells were washed and resuspended in FACS buffer, and 7AAD was 
added 5 minutes before analysis. Control CMV pp65–specific CD8+ T cells 
were detected in all CMV-seropositive patients before and after immuniza-
tion (data not shown). A negative HLA-A*0201/HIV gag peptide tetramer 
control was included. 25,000 events in the CD8+ gate were collected using 
a hierarchical gating strategy that included FSC/SSC and excluded 7AAD+ 
(dead) cells and CD4+CD14+CD19+CD56+ cells. Data were acquired and 
analyzed using Flow-Jo software.
Cytokine production. DC IL-12p70 and IL-12p40 production was mea-
sured by ELISA (eBioscience) according to the manufacturer’s instruc-
tions. Production of additional cytokines and chemokines by DCs was 
determined using MILLIPLEX map Human Cytokine Panels I and II (EMD 
Millipore). For production of cytokines by T cells, G280-9V–specific 
T cells were expanded using mDCs and AT-SCT as described previously 
(25). The frequency of antigen-specific T cells after secondary stimulation 
was 2%–52%, as determined by HLA-A*0201/peptide tetramers (NIH tetra-
mers Facility or Beckman Coulter). T cells were restimulated as described 
previously (25), supernatants were collected at 24 hours, and production of 
cytokines was determined using MILLIPLEX map Human Cytokine Panel 
I (EMD Millipore).
qRT-PCR. qRT-PCR was performed as described previously (26). cDNAs 
were prepared (2 μg total RNA), and cDNA samples were amplified in trip-
licate using a GeneAmp 5700 sequencer detector (Applied Biosystems). 
Primers used were IL-12p35 (Hs00168405_m1) and ITGAX (integrin alpha 
X, referred to herein as CD11c; Hs01015070_m1). Transcript levels were 
calculated using the relative standard curve method, using CD11c tran-
script levels to normalize values.
51Cr release and T2 assays. 51Cr release assays to measure specific lysis 
have been described previously (26, 62). Melanoma cell lines DM6 (HLA-
A2+gp100+) and A375 (HLA-A2+gp100–) were labeled with 25 μCi 51Cr for 
1 hour, washed, and tested as targets in a standard 4-hour assay. Effectors 
were generated using PBMCs collected after D3 and cultured for 12 days 
in the presence of peptide (40 μg/ml) and IL-2 (50 U/ml every other day). 
Vaccine-induced antigen-specific T cells were characterized using HLA-
A*0201/peptide dextramers (Immudex). To determine the avidity (effective 
concentration at 50% maximal lysis) of vaccine-induced T cells for antigen, 
T2 cells were pulsed with titrated G209-2M or G280-9V peptide concen-
trations for 1 hour in serum-free media followed by 51Cr (25 μCi) labeling 
for 1 hour, washed twice, and tested using vaccine-induced gp100-specific 
T cells in a standard 4-hour assay.
Statistics. Student’s t tests were 2-tailed (GraphPad Prism software, version 
5.0). Data are presented as mean ± 1 SD, unless otherwise indicated. Cox 
regression analysis followed by likelihood-ratio test was used to evaluate 
whether (loge) IL-12p70 (sum) production added statistically significant 
information to a model of TTP. Kaplan-Meier TTP model was used to test 
whether cytokine ratios added statistically significant information to a 
model of TTP. Wilcoxon matched-pairs analysis was used to compare IL-
12p70 production between patients and healthy donors (GraphPad Prism 
software, version 5.0). All P values less than 0.05 were considered significant, 
except the Cox proportional hazard model, which used a lower threshold 
of significance (P < 0.048) to adjust for 1 interim analysis of this endpoint.
Study approval. This study (IRB no. 07-0652) was approved by the Site-
man Cancer Center Protocol Review and Monitoring Committee and the 
Washington University School of Medicine Human Research Protection 
Office. All patients provided written informed consent for the clinical 
study. The FDA approved procedures for DC manufacturing and admin-
trial patients, leukapheresis was performed prior to treatment and after D3 
and D6. Patients were not prescreened for IL-12p70 DC production prior 
to treatment. Prior to treatment, baseline imaging was performed by MRI 
scan of brain and CT scan of the chest/abdomen/pelvis with i.v. contrast.
Peptides. gp100-derived peptides G154 (KTWGQYWQV), G209-2M 
(IMDQVPFSV), and G280-9V (YLEPGPVTV) and CMV pp65–derived 
peptide 495 (NLVPMVATV) were obtained lyophilized (>95% purity; Amer-
ican Peptide Company). Peptides were dissolved in 1% DMSO in sterile 
water and tested for sterility, purity, endotoxin, and mycoplasma.
Cyclophosphamide treatment and DC preparation. Cyclophosphamide (300 
mg/m2) was given 72 hours prior to D1 with the intention of eliminating 
Tregs (61). Treg quantification was performed as described in Supplemen-
tal Figure 2. All mDC vaccine doses were prepared at the time of immuni-
zation from either freshly isolated (D1) or cryopreserved (D2–D6) PBMCs 
(all derived from the same leukapheresis collection). A GMP-grade CD40L-
expressing K562 cell line (referred to as K463H), used for maturation of 
DCs, was generated, selected, and maintained under serum-free (Stemline, 
S1694 media) conditions (see Supplemental Figure 1). For each vaccine 
dose, monocyte-derived iDCs were generated as described previously (62) 
by culturing the PBMC adherent fraction in RPMI 1640 with 1% human 
AB-serum (DC media) supplemented with 100 ng/ml GM-CSF (Berlex) 
and 20 ng/ml IL-4 (CellGenix). 6 days after culture initiation, iDCs were 
harvested, washed in PBS, and cultured for an additional 24 hours in DC 
media (iDC control) or DC media with irradiated (100 Gy) K463H (5:1 
DC/K463H ratio) and 100 U/ml IFN-γ (Actimmune; InterMune Inc.) to 
generate mDCs. Comparison of the K463H line with other commercial-
ly available CD40L reagents in IL-12p70 induction is shown in Supple-
mental Figure 1, B and C. 2 hours prior to infusion, mDCs were pulsed 
(50 μg/106 cells/ml) separately with 1 of 4 peptides: G154, G209-2M, G280-
9V, or CMV pp65. For D1 only, influenza virus vaccine (Sanofi Pasteur) was 
added to provide a source of recall antigen for CD4+ T cells. For infusion, 
mDCs were resuspended in 50 ml normal saline supplemented with 5% 
human serum albumin and administered over 30 minutes by i.v. infusion 
after premedication with 650 mg acetaminophen.
DC immunizations. mDC infusions were given i.v. every 3 weeks for 6 
doses in the outpatient clinic. A restaging CT scan of the chest/abdomen/
pelvis with i.v. contrast was performed after D3 and D6 and then every 
2 months thereafter until disease progression. If clinical or radiographic 
disease progression was evident, the patient was removed from the study. 
For D1, patients received 1.5 × 107 DCs per peptide (6 × 107 DCs total); 
for D2–D6, patients received 5 × 106 DCs per peptide (2 × 107 DCs total). 
The purpose of this trial was to determine the safety, tolerability, and clini-
cal and immunological outcomes of immunization using peptide-pulsed 
CD40L/IFN-γ mDCs. Patients underwent clinical evaluation prior to each 
mDC infusion. Toxicities and adverse effects were graded according to the 
National Cancer Institute Common Toxicity Scale (version 3.0). Clinical 
response was assessed by measurement of assessable metastatic deposits by 
CT scan, MRI scan, or direct measure of cutaneous deposits. The RECIST 
(v1.0) group system was used (24).
Immunologic monitoring. Immunologic analysis to evaluate the kinetics 
and magnitude of T cell response to gp100 peptides was performed using 
PBMCs collected weekly (prior to vaccination and until week 21; Figure 
1B). Fresh PBMCs obtained by Ficoll-Hypaque gradient centrifugation 
were adjusted to 2 × 106 cells/ml in Stemline media (Sigma-Aldrich) con-
taining 5% human AB-serum, and dispersed at 1 ml/well in 24-well plates. 
Cultures were set up for the gp100 peptides and the CMV pp65 peptide 
(positive peptide control; data not shown). Cultures were pulsed with 40 
μg/ml peptide and 50 U/ml IL-2 fed starting at 48 hours and every other 
day thereafter. On day 12 (peak of response; our unpublished observation), 
cultures were harvested, counted, and stained for flow cytometry analysis. 
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